About the Consortium

Who We Are

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.


The MCDC is currently recruiting a broad and diverse group of interested parties that includes representatives from large businesses, small businesses, traditional and non-traditional government contractors, academic research institutions, and not-for-profit organizations with collective expertise in the technology areas specifically related to the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) mission.


See Our Leadership

Leadership

Robert V. House, Ph.D., FATS
Ology Bioservices
Executive Committee Chair and Small Business Representative

Dr. House is the Senior Vice President, Government Contracts at Ology Bioservices. Dr. House has nearly 30 years of experience in basic and applied biomedical research and development, specializing in the assessment of inadvertent and therapeutic immunomodulation. Dr. House earned his B.A. in Zoology, M.S. in Public Health and Ph.D. from the University of North Carolina. He is the author, co-author or editor of more than 100 articles and books, is an Adjunct Professor at George Mason University where he teaches medical countermeasure development.

Pete Latham, M.S., PgMP
Latham BioPharm Group
Executive Committee Vice-Chair and Small Business Representative

Peter Latham is Founder and President of Latham BioPharm Group (LBG), a consulting firm with expertise in the formation of product development teams and the funding and management of Life Science programs. Dr. Latham brings deep industry knowledge and skills to both government and commercially-funded biodefense, infectious diseases and pandemic response programs. He has thirty years of experience in general management with over twenty years specializing in financial, strategic, program management, and business development consulting. Dr. Latham has successfully managed multiple government programs and remains actively engaged in biodefense and pandemic response, having served as Systems Integrator for DOD and HHS programs. Dr. Latham earned his M.S., Management from MIT Sloan School of Management.

Michael G. MacNaughton, Ph.D.
Southwest Research Institute
Executive Committee Treasurer and Large/Non-Profit Representative

Dr. MacNaughton is the Vice President of the Chemistry & Chemical Engineering Division of the Southwest Research Institute. For over 40 years, Dr. MacNaughton has been active in multidisciplinary engineering and chemistry research programs. He provides management leadership for programs in chemical and biological warfare defense environmental engineering, and analytical chemistry. A retired U.S. Air Force Colonel, Dr. MacNaughton has a Ph.D. in Environmental Engineering from Stanford University, a M.S. in Environmental Engineering from the University of Michigan, and a B.S. in Civil Engineering from Michigan State University.

Veronica Hall, Ph.D.
Emergent BioSolutions
Executive Committee Large/Non-Profit Representative

Dr. Hall, Senior Director of External Development, has over 15 years of experience in the life sciences with a unique combination of experience in molecular signaling, immune response, and vaccine and therapeutic product development from preclinical development to licensure, and management of a multifaceted team that identifies customer requirements and is the voice of the customer to the product development team. Dr. Hall earned her Ph.D. in Biochemistry and Cell Biology from Rice University in Houston, TX

David Moore, DVM, Ph.D.
Chief Operating Officer, SciTech Services, Inc.
Executive Committee Small Business Representative

Dave brings 40 years of successful Government and commercial scientific and leadership experience to his new appointment as a member of the MCDC Executive Committee. Prior to joining SciTech, Dr. Moore served 18 years with Battelle as V.P. for Business Development for Life Sciences Research. Prior to joining Battelle, he served 21 years in the U.S. Army concluding his military career as a Colonel and Director of the Medical Chemical Defense Research Program at Ft. Detrick, MD and Deputy Commander of the U.S. Army Medical Research Institute for Chemical Defense at Aberdeen Proving Ground, MD. For 15 years he served as the Editor for Antidote Development for the Journal of Drug and Chemical Toxicology. Dr. Moore also served two terms as a full member of the Committee on Toxicology of the National Research Council and from 2008-2012 was appointed a member of the U.S. Air Force Scientific Advisory Board.

Mark Martin, Ph.D.
Janssen/Johnson & Johnson
Executive Committee Large/Non-Profit Representative

Dr. Martin is a Director in the Global Government Grants Office (G3O) of Johnson & Johnson/Janssen Pharmaceuticals where he is engaged in forming R&D partnerships between J&J entities and external organizations, especially the US Government. Previously, Dr. Martin was with the National Institutes of Health and was a scientific leader at IGEN (later BioVeris), a company which pioneered electrochemiluminescence (ECL) detection technology. He is also a serial entrepreneur and inventor having founded three biotechnology companies based in part on his approximately 150 issued patents. Dr. Martin was educated at the University of North Dakota (Ph.D., Biochemistry and Molecular Biology), Harvard University (Postdoctoral, Biophysics), and Oxford University (Postdoctoral, Pathology).

Ronald K. Poropatich, M.D.
University of Pittsburgh
Executive Committee Academic Representative

Dr. Poropatich is the Executive Director of the Center for Military Medicine Research, Health Sciences at the University of Pittsburgh and served as the Deputy Director of the US Army’s Telemedicine and Advanced Technology Research Center. Dr. Poropatich received his medical degree from Drexel University, completed a residency and internship at the Walter Reed Army Medical Center, and is a diplomate of the American Board of Internal Medicine in Medicine, Pulmonary and Critical Care Medicine, a Fellow of the American College of Physicians, Chest Physicians, and Fellow and past president of the American Telemedicine Association.

Larry Zeitlin, Ph.D.
President, Mapp Biopharmaceutical and LeafBio, Inc
Executive Committee Small Business Representative

Larry received a B.A. in Biophysics and his doctorate in Reproductive Biology from The Johns Hopkins University. After serving as a Research Scientist at ReProtect, LLC (Baltimore, MD), and a Senior Scientist at Epicyte Pharmaceutical (San Diego, CA), together with Dr. Kevin Whaley, he co-founded Mapp Biopharmaceutical and LeafBio, Inc. (San Diego, CA). He has been an adjunct faculty member of the Biodesign Institute at Arizona State University since 2004. Larry’s career focus has been on the development of monoclonal antibody based products to address unmet public health needs in infectious disease.

Mike Stebbins, Ph.D.
Advanced Technology International
Consortium Management Firm

Dr. Stebbins is the Director of Operations with Advanced Technology International (ATI) and serves as Consortium Manager for the Medical CBRN Defense Consortium (MCDC) for which ATI serves as the Consortium Management Firm. Throughout his 9+ year tenure at ATI, Dr. Stebbins has served as the Director of Business Planning and Development where he led the capture and startup of the $70M, 5-year UI LABS-led Digital Manufacturing and Design Innovation Institute (DMDII), one of several National Network for Manufacturing Innovation (NNMI) institutes solicited by DoD. Dr. Stebbins also had significant roles on ATI-led programs looking at the epidemiological effects of exposure to the vanadium manufacturing process as well as demonstrating and validating the impact of copper on reducing levels of harmful microbes. Prior to ATI Dr. Stebbins worked in the industrial chemical, environmental testing and pharmaceuticals industries. Dr. Stebbins earned his Ph.D. in analytical chemistry from the University of Tennessee, Knoxville and his B.S. in chemistry from the College of Charleston.

Mica Dolan, CPCM
Advanced Technology International
Consortium Management Firm

Mrs. Dolan is a Corporate Manager supporting Advanced Technology International (ATI) and is a Certified Professional Contracts Manager (CPCM). She currently serves as the Contractual Team Lead for the Innovative Prototypes division, including the multi-billion dollar Department of Defense Ordnance Technology Consortium (DOTC) program, the Vertical Lift Consortium (VLC) and the National Spectrum Consortium. Her current duties now include the MCDC. ATI serves as the Consortium Management Firm for all of these. As the Contractual Team Lead for these efforts, Mrs. Dolan is responsible for overseeing all solicitation development, cost proposal analysis, proposal preparation and contracting under these programs including preparing, administering, negotiating and monitoring various types of contracts; pre-award and post award activities in support of ATI programs; the preparing of ATI cost proposals; monitoring contract budgets; and preparation of closeout documents. Mrs. Dolan was awarded her Masters Degree in Business Administration from the Citadel and her Bachelor of Science in Finance and Human Resources Management with a minor in French from the University of South Carolina.